1
Clinical Trials associated with NK cell therapy (CellProtect Nordic Pharmaceuticals)An Open, Randomised, Controlled, Phase II Trial of CellProtect in Combination With Isatuximab Antibody Versus Isatuximab Antibody Alone as Maintenance Treatment in Patients With Multiple Myeloma Undergoing High Dose Treatment
Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to Isatuximab for the treatment of patients with newly diagnosed multiple myeloma who are eligible for stem cell transplantation (SCT) as maintenance after SCT.
100 Clinical Results associated with NK cell therapy (CellProtect Nordic Pharmaceuticals)
100 Translational Medicine associated with NK cell therapy (CellProtect Nordic Pharmaceuticals)
100 Patents (Medical) associated with NK cell therapy (CellProtect Nordic Pharmaceuticals)
100 Deals associated with NK cell therapy (CellProtect Nordic Pharmaceuticals)